AI in medical communications

Integration of AI in Medical Communications: A Roadmap

AI in medical communications: Why it matters now Artificial intelligence (AI) is rapidly reshaping medical communications (MedComms), driven by the necessity for personalization, efficiency, and speed in content delivery. As pharmaceutical companies face mounting competition, the demand for innovative communication strategies to communicate complex data and information, as early as the critical pre-launch phase, is…...
Read More

Top Stories

Nelson memo

The Nelson Memo: Igniting a Global Open Data

The landscape of scientific research is undergoing a seismic...
Rare diseases

Rare Diseases – An Evolving Medical

A disease is considered rare when it affects fewer than 1 in...

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...
Stakeholder perspectives on digital scientific content

Digital Scientific Content: Stakeholder Perspectives

What do the different relevant stakeholder groups truly expect from pharma-generated scientific content?...
How Can Preprints Drive Trust In Science?

How Can Preprints Drive Trust in Science?

By tagging preprints with various indicators, badges may represent quality, rigor, and scope. In doing...
equity diversity and inclusion

How to Incorporate and Drive Equity, Diversity, and Inclusion in Medical Communications and Publications

A roadmap on how to drive advocacy for EDI in medical communications and publications and...
reimagining scientific communications

Scientific Communication Strategies for Digital Transformation

Read how digital transformation strategies can help to rethink workflows for future readiness and scale-up...
Using digital enhancements to maximize engagement

Using Digital Enhancements to Maximize Engagement: How Are Pharma and Publishers Embracing Digital?

Best practices to implement digital enhancements and measure effectiveness...
Pros and cons of preprints for pharma

Preprints and Pharma: What Works and What Doesn’t

Pharma is cautious of preprints. But should this change? Let’s weigh the pros & cons...

Learn more ABOUT our company.